476472-02-3

Basic information

• Product Name: 1-(6-METHYLPYRIDYL)-2-QUINOLIN-4-YL ETHANONE
• Synonyms: 1-(6-METHYLPYRIDYL)-2-QUINOLIN-4-YL ETHANONE;1-(6-Methylpyridin-2-yl)-2-(quinolin-4-yl)ethanone
• CAS NO: 476472-02-3
• Molecular Formula: C₁₇H₁₄N₂O
• Molecular Weight: 262.31
• Mol File: 476472-02-3.mol

Chemical Properties

• Boiling Point: 449.9°C at 760 mmHg
• Flash Point: 225.7°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 2.75E-08mmHg at 25°C
• Refractive Index: 1.649
• CAS DataBase Reference: 1-(6-METHYLPYRIDYL)-2-QUINOLIN-4-YL ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-METHYLPYRIDYL)-2-QUINOLIN-4-YL ETHANONE(476472-02-3)
• EPA Substance Registry System: 1-(6-METHYLPYRIDYL)-2-QUINOLIN-4-YL ETHANONE(476472-02-3)

Safety Data

• Hazardous Substances Data: 476472-02-3(Hazardous Substances Data)

Usage

Molecular Structure

Complex molecular structure

Class of Compounds

Quinolones and derivatives

Usage

Primarily used for research purposes

Presence in Everyday Products

Not commonly found

Chemical Properties

Being explored

Potential Applications

Being explored

Further Research

Needed to fully understand potential uses and effects

InChI:InChI=1/C17H14N2O/c1-12-5-4-8-16(19-12)17(20)11-13-9-10-18-15-7-3-2-6-14(13)15/h2-10H,11H2,1H3

Upstream product

• 491-35-0 C₆H₄NCH₂CHCCH₂ 
• 13602-11-4 6-methylpicolinic acid methyl ester 
• 4363-93-3 quinoline-4-carboxaldehyde 
• 614750-85-5 diphenyl (6-methylpyridin-2-yl)(phenylamino)methylphosphonate 
• 39640-51-2 ethyl 6-methylpyridine-2-carboxylate 
• 934-60-1 6-methyl-2-pyridinecarboxylic acid 

Downstream Products

• 607737-87-1 4-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)quinoline 

Relevant articles and documents

BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5

The present invention relates to novel benzylamide derivatives of formula (I) to processes for the preparation of said compounds; to pharmaceutical compositions comprising said compounds and to said compounds for use in the treatment of pathological conditions or diseases that can improve by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as diseases and disorders associated to fibrotic conditions of gastrointestinal system, skin and eyes, to methods for the treatment and/or prevention of said diseases or pathological conditions and to combinations comprising said compounds and further comprising therapeutically effective amounts of other therapeutic agents useful for the treatment of said diseases or pathological conditions.

Synthesis and evaluation of the HIF-1α inhibitory activity of 3(5)-substituted-4-(quinolin-4-yl)- and 4-(2-phenylpyridin-4-yl)pyrazoles as inhibitors of ALK5

The transcription factor hypoxia-inducible factor-1α (HIF-1α) plays an important role in apoptosis, metastasis, and proliferation and is recognized as an important potential therapeutic target for cancer. Six series of 3(5)-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)pyrazoles (11a–d, 12a–d, and 18a–d) and 3(5)-(6-methylpyridin-2-yl)-4-(2-phenyl-pyridin-4-yl)pyrazoles (19a–d, 20a–d, and 21a–d) were synthesized and evaluated for activin receptor-like kinase 5 (ALK5) and HIF-1α inhibitory activity at the enzyme and cell levels. The effect of the lead compound 20d (J-1012) on HIF-1α activation in HCT116 cells was investigated. J-1012 markedly decreased the hypoxia-induced or TNF-induced accumulation of HIF-1α protein dose-dependently. Analysis revealed that J-1012 inhibited HIF-1α protein synthesis, without affecting the degradation of HIF-1α protein. Furthermore, by inhibiting the activation of HIF-1α, J-1012 suppressed the metastasis and proliferation and promoted apoptosis of HCT116 cells. These results suggest that J-1012 may be a potential therapeutic agent against human colon cancer.

Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors

A series of 2-pyridyl-substituted pyrazoles (16a-d, 17, 18, and 28a-e) and imidazoles (22 and 23) has been synthesized and evaluated for their ALK5 inhibitory activity in cell-based luciferase reporter assays. Among them, 3-(3-(6-methylpyridin-2-yl)-4-(qu

Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

We have expanded our previously reported series of pyrazole-based inhibitors of the TGF-β type I receptor kinase domain (TβR-I) to now include new 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole analogues. Limited examination of the SAR of this new series in both e

NOVEL PYRAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS

Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of trans

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain

Pyrazole-based inhibitors of the transforming growth factor-β type I receptor kinase domain (TβR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TβR-I receptor kinase domain.